Our focus is on market access strategy for new pharmaceuticals, bio-technologies, diagnostics, preventative approaches and digital health technologies.

  • Evidence generation from PH 1b to post-launch
  • HTA and payer requirement mapping
  • Evidence uncertainty impact assessment
  • Evidence repository development from Phase 1b to post-launch
  • Evidence mitigation identification
  • Evidence source assessment – clinical trial and RWD planning
  • Clinical guideline mapping
  • Patient pathway analysis
Commercial Planning
  • Early Scientific Advice – HTA alone and jointly with regulatory
  • ‘Mock’ scientific advice
  • Early access planning: ConcentreTM – planning along ‘value in health’
  • Stakeholder mapping at national and sub-national levels
  • Market access pathway determination
  • Integrated evidence planning – from regulatory, policy/advocacy to HTA/payer and budget holder management
  • Post-launch value contingency planning
Price and Contracting
  • Pricing based on value demonstration over time
  • Pricing based on payer priorities in budgeting
  • Economically justifiable pricing
  • Price reference modelling – internal and international
  • Forecast modelling
  • Net present value modelling
  • Value-based procurement planning – local budget management
Communicating Patient Benefit
  • Value proposition and message development
  • Value dossiers
  • Objection handlers
Service Techniques

In-house assessment, Advisory boards – virtual and F2F, GAP analysis, SWOT, WAR Gaming, PEST, Landscape assessments, Primary research, Data analysis


National payer network across US, Europe, Asia and South America, Local payer networks in Europe, Canada and US

Let’s work together.
Telephone +1 585 280 0720 United States + 49 151 176 301 42 Germany +33 69 55 18 18 0 France